Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Biospace

Published November 16, 2026 · Updated November 17, 2026

Serious adverse events mar robust efficacy data for Helus' psychedelic in major depression

Read the full story at Biospace

A proprietary, deuterated analog of psilocin—the active form of the psilocybin hallucinogenic found in magic mushrooms —HLP003 holds FDA Breakthrough.

Surfaced by 3 Google Alerts

  • Magic mushrooms
  • Psychedelics europe
  • Psychedelic biotech